Emami Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/cat93e0koug4qocostqhfx4r.pdf

Key Takeaways


Demand & Volume Dynamics

Mohan Goenka: "Yes if you see last four years, Kesh King oil is at a 5% growth CAGR. When you compare pre-COVID levels, so this is one-off, a decline of 13%. It's not that the oil is declining."

Brand & Segment Performance

Segment / BrandTrendCommentary
Pain portfolio▲ ResilientAt 26% of revenues and non-seasonal, it provided stability while winter products declined.
Winter portfolio▼ Declined ~9%Delayed, low-intensity winter hit BoroPlus Cream, Navratna Oil and Cool Talc; Chyawanprash dragged healthcare flat.
Kesh King▼ 13% declinePremium hair oil facing downtrading stress; onion and other new ranges performing better. Management expects bounce-back to 6-8% growth once market revives.
7 Oils▼ ImpactedDiscretionary slowdown weighed on performance this quarter.
Healthcare▬ FlatBrands grew 5-7% but Chyawanprash decline dragged the portfolio; new launches provide entry into large categories.
International▲ RobustMENAP region drove performance despite currency depreciation, Bangladesh elections, and Red Sea disruptions.
D2C brands▲ Scaling fastMan Company EBITDA turned positive on ~80% growth; Brillare losses narrowed from 40-45% to minus 20%.

New Launches & Innovation

Mohan Goenka: "now that the margins are pretty high in toothpaste, particularly this Ayurvedic segment, we strongly believe that Zandu has right to win because Zandu, in Ayurveda is a very well established brand and we were working on the formulation for quite some time, I think we have a winner formulation."

Margins & Input Costs

Gul Raj Bhatia: "It would not be at a premium like we would have other products in the category because there is a certain price point in the category, but definitely in terms of the formulation, we got certain ingredients which are much more efficacious."

D2C & Channel Strategy

Mohan Goenka: "Man Company, there is a big shift which was a negative EBITDA margin has become positive because our growth has been almost 80%. So, due to the scale up, the brand is now making profits. Same is with Brillare, the negative EBITDA margins which was in the tune of almost 40%-45% has come down to minus 20%."

Guidance & Commitments

CommitmentSpecificsTimeline
Volume growth target6% to 8% volume growthNo specific quarter; market conditions cited as a caveat
Price increaseRoughly 3% price increaseNext year (FY25)
Healthcare growthStrong double-digit growthCurrent and going-forward quarters/years
Pledge reductionBring pledge down to single digits from current 12%No specific quarter given
Effective tax rateAround 10% considering MAT credit entitlementsQ4 FY24 and next year
Kesh King recoveryBounce back to at least 6% to 8% growth once market revivesConditional on market revival; possibly Q4

Key Metrics

MetricQ3 FY24
Consolidated revenue₹996 cr, +1.4% YoY; volume declined 0.9%
Domestic non-winter portfolio growth+5%
Gross margin68.8%, expanded 290 bps YoY
EBITDA₹315 cr, +7% YoY; margin 31.6%, up 170 bps
PAT₹258 cr, +9% YoY; margin 25.9%, up 180 bps
9M FY24 revenue growth~5% YoY
9M FY24 EBITDA margin27.5%, up 170 bps YoY
9M FY24 PAT₹575 cr, +16% YoY
International business growth+8% in INR terms, +11% in constant currency
Navratna and Dermicool range growth+7%
Pain management portfolio growth+3%; represents 26% of revenues
Healthcare range (ex-Chyawanprash and honey) growth+3%; overall healthcare flat
BoroPlus growth-9%, due to late onset and mild winter
Male Grooming range growth-6%
Kesh King range growth-13%; 4-year CAGR +5% vs pre-COVID
Helios and Brillare Science growth+80%
Modern trade and e-commerce saliency22% of sales; modern trade +10%, e-commerce +17%
7 Oils in One growth-5% in Q3; flat for 9M FY24
Winter portfolio decline~9%
Man Company profitabilityEBITDA positive, from negative; growth ~80%
Brillare EBITDA margin-20%, improved from -40% to -45%
Promoter pledge12%
Effective tax rate (9M FY24)7.7%; expected ~10% for Q4 and next year
Net cash~₹400 cr
Second interim dividend₹4 per share (400%)